REFERÊNCIAS 1. Schenker JG, Cain JM. FIGO Committee Report. FIGO Committee for the Ethical Aspects of Human Reproduction and Women s Health. International Federation of Gynecology and Obstetrics. Int J Gynaecol Obstet. 1999;64(3):317-22. 2. Aleman A, Althabe F, Belizán J, Bergel E. Bed rest during pregnancy for preventing miscarriage. Cochrane Database Syst Rev. 2005;(2):CD003576. 3. World Health Organization. The prevention and management of unsafe abortion: report of a technical Working Group. Geneva: WHO; 1992. 4. World Health Organization. Safe abortion: technical and policy guidance for health systems. 2nd ed. Geneva: WHO; 2012. 5. Victora CG, Aquino EM, Do Carmo Leal M, Monteiro CA, Barros FC, Szwarcwald CL. Saúde de mães e crianças no Brasil: progressos e desafios. The Lancet. 2011;377(9780):1863-76. 6. Sedgh G, Singh S, Shah IH, Ahman E, Henshaw SK, Bankole A. Induced abortion: incidence and trends worldwide from 1995 to 2008. Lancet. 2012;379(9816):625-32. 7. Schenck M, Thibaut C, Simon S, Giugliani C, Gorgoroso M. Los derechos de las mujeres en América Latina frente al aborto inseguro e ilegal. Revista de Información y Debate. 2013;55(1):14-7. 8. Cruz Jaimes G. Honda deuda legal en derecho al aborto [Internet]. Mexico: IPS; 2011 [capturado em 21 jan. 2013]. Disponível em: http://ipsnoticias.net/nota.asp?idnews=99235. 9. Benson J. Evaluating abortion-care programs: old challenges, new directions. Stud Fam Plann. 2005;36(3):189-202. 10. Grimes DA, Benson J, Singh S, Romero M, Ganatra B, Okonofua FE, et al. Unsafe abortion: the preventable pandemic. Lancet. 2006;368(9550):1908-19. 11. Singh S. Hospital admissions resulting from unsafe abortion: estimates from 13 developing countries. Lancet. 2006;368(9550):1887-92. 12. Shah I, Ahman E. Unsafe abortion: global and regional incidence, trends, consequences, and challenges. J Obstet Gynaecol Can. 2009;31(12):1149-58. 13. World Health Organization. Unsafe abortion: global and regional estimates of the incidence of unsafe abortion and associated mortality in 2008. 6th ed. Geneva: WHO; 2011.
14. Bartlett LA, Berg CJ, Shulman HB, Zane SB, Green CA, Whitehead S, et al. Risk factors for legal induced abortion-related mortality in the United States. Obstet Gynecol. 2004;103(4):729-37. 15. World Health Organization. Trends in maternal mortality: 1990-2010. Geneva: WHO/UNICEF/UNFPA/World Bank; 2012. 16. Parpinelli MA, Faúndes A, Cecatti JG, Surita FGC, Pereira BG, Passini R Júnior, et al. Subnotificação da mortalidade materna em Campinas: 1992 a 1994. Rev Bras Ginecol Obstet. 2000;22(1):27-32. 17. World Health Organization. Twentieth world health assembly resolution 20.14: health aspects of family planning. Geneva: WHO; 1967. 18. World Health Organization. Reproductive health strategy to accelerate progress towards the attainment of international development goals and targets. Geneva: WHO; 2004. 19. Brasil. Ministério da Saúde. Atenção humanizada ao abortamento: norma técnica. Brasília: MS; 2005. 20. Brasil. Ministério da Saúde. Atenção humanizada ao abortamento: norma técnica. 2. ed. Brasília: MS; 2011. 21. Prada E, Kestler E, Sten C, Duaphinee L, Ramírez L. Aborto y atención postaborto en Guatemala: informe de profesionales de la salud e instituciones de salud; informe ocasional. New York: Instituto Guttmacher; 2005. 22. Tietze C, Lewit S. Joint Program for the Study of Abortion (JPSA): early medical complications of legal abortion. Stud Fam Plann. 1972;3(6):97. 23. Edelman DA, Brenner WE, Berger GS. The effectiveness and complications of abortion by dilatation and vacuum aspiration versus dilatation and rigid metal curettage. Am J Obstet Gynecol. 1974;119(4):473-80. 24. Cates W Jr, Grimes DA, Smith JC, Tyler CW Jr. Legal abortion mortality in the United States: epidemiologic surveillance, 1972-1974. JAMA. 1977;237(5):452-5. 25. Hart G, Macharper T. Clinical aspects of induced abortion in South Australia from 1970-1984. Aust N Z J Obstet Gynaecol. 1986;26(3):219-24. 26. Greenslade FC, Benson J, Benson J, Henderson V, Wolf M, Leonard A. Summary of clinical and programmatic experience with manual vacuum aspiration. Carrboro: IPAS; 1993. 27. Baulieu EE, Rosenblum M. The abortion pill. New York: Simon & Schuster; 1990. 28. Baulieu EE. Contragestion by antiprogestin: a new approach to human fertility control. In: Porter R, O'Connor M; Ciba Foundation. Abortion: medical progress and social implications. London: Pitman; 1985. p. 192-210.
29. Kulier R, Kapp N, Gülmezoglu AM, Hofmeyr GJ, Cheng L, Campana A. Medical methods for first trimester abortion. Cochrane Database Syst Rev. 2011;(11):CD002855. 30. Jain JK, Dutton C, Harwood B, Meckstroth KR, Mishell DR Jr. A prospective randomized, double-blinded, placebo-controlled trial comparing mifepristone and vaginal misoprostol to vaginal misoprostol alone for elective termination of early pregnancy. Hum Reprod. 2002;17(6):1477-82. 31. Esteve JL, Varela L, Velazco A, Tanda R, Cabezas E, Sánchez C. Early abortion with 800 micrograms of misoprostol by the vaginal route. Contraception. 1999;59(4):219-25. 32. Bugalho A, Mocumbi S, Faúndes A, David E. Termination of pregnancies of <6 weeks gestation with a single dose of 800 microg of vaginal misoprostol. Contraception. 2000;61(1):47-50. 33. Say L, Kulier R, Gülmezoglu M, Campana A. Medical versus surgical methods for first trimester termination of pregnancy. Cochrane Database Syst Rev. 2005;(1):CD003037. 34. Peyron R, Aubény E, Targosz V, Silvestre L, Renault M, Elkik F, et al. Early termination of pregnancy with mifepristone (RU 486) and the orally active prostaglandin misoprostol. N Engl J Med. 1993;328(21):1509-13. 35. Ulmann A, Silvestre L. RU486: the French experience. Hum Reprod. 1994;9 Suppl 1:126-30. 36. Hollander D. Mifepristone and vaginal misoprostol are effective, acceptable and inexpensive medical abortion regimen. Fam Plan Perspect. 1995;27(5):223-4. 37. Blum J, Winikoff B, Gemzell-Danielsson K, Ho PC, Schiavon R, Weeks A. Treatment of incomplete abortion and miscarriage with misoprostol. Int J Gynaecol Obstet. 2007;99 Suppl 2:S186-9. 38. Faúndes A, Fiala C, Tang OS, Velasco A. Misoprostol for the termination of pregnancy up to 12 completed weeks of pregnancy. Int J Gynaecol Obstet. 2007;99 Suppl 2:S172-7. 39. Von Hertzen H, Piaggio G, Wojdyla D, Marions L, My Huong NT, Tang OS, et al. Two mifepristone doses and two intervals of misoprostol administration for termination of early pregnancy: a randomised factorial controlled equivalence trial. BJOG. 2009;116(3):381-9. 40. Raghavan S, Comendant R, Digol I, Ungureanu S, Dondiuc I, Turcanu S, et al. Comparison of 400 mcg buccal and 400 mcg sublingual misoprostol after mifepristone medical abortion through 63 days LMP: a randomized controlled trial. Contraception. 2010;82(6):513-9.
41. Von Hertzen H, Huong NTM, Piaggio G, Bayalag M, Cabezas E, Fang AH, et al. Misoprostol dose and route after mifepristone for early medical abortion: a randomised controlled noninferiority trial. BJOG. 2010;117(10):1186-96. 42. Wildschut H, Both MI, Medema S, Thomee E, Wildhagen MF, Kapp N. Medical methods for mid-trimester termination of pregnancy. Cochrane Database Syst Rev. 2011;(1):CD005216. 43. Ho PC, Blumenthal PD, Gemzell-Danielsson K, Gómez Ponce de León R, Mittal S, Tang OS. Misoprostol for the termination of pregnancy with a live fetus at 13 to 26 weeks. Int J Gynaecol Obstet. 2007;99 Suppl 2:S178-81. 44. Solo J. Easing the pain: pain management in the treatment of incomplete abortion. Reprod Health Matters. 2000;8(15):45-51. 45. Suprapto K, Reed S. Naproxen sodium for pain relief in first-trimester abortion. Am J Obstet Gynecol. 1984;150(8):1000-1. 46. Matambo J, Moodley J, Chigumadzi P. Analgesia for termination of pregnancy. S Afr Med J. 1999;89(8):816. 47. Jackson E, Kapp N. Pain control in first-trimester and second-trimester medical termination of pregnancy: a systematic review. Contraception. 2011;83(2):116-26. 48. Livshits A, Machtinger R, David LB, Spira M, Moshe-Zahav A, Seidman DS. Ibuprofen and paracetamol for pain relief during medical abortion: a double-blind randomized controlled study. Fertil Steril. 2009;91(5):1877-80. LEITURAS RECOMENDADAS Brasil. Ministério da Saúde. Secretaria de Atenção à Saúde. Departamento de Ações Programáticas Estratégicas. Área Técnica de Saúde da Mulher. Atenção humanizada ao abortamento: norma técnica. Brasília: MS; 2005. Estabelece como deve ser o atendimento à mulher em situações de aborto. Brasil. Ministério da Saúde. Secretaria de Atenção à Saúde. Departamento de Ações Programáticas Estratégicas. Área Técnica de Saúde da Mulher. Prevenção e tratamento dos agravos resultantes da violência sexual contra mulheres e adolescentes: norma técnica. 2. ed. atual. ampl. Brasília: MS; 2005. Descreve os procedimentos para proceder ao aborto legal em caso de estupro. Federación Latinoamericano de Sociedades de Obstetricia y Ginecología. Uso de misoprostol en obstetricia y ginecología. 2. ed. [S.l.]: Ipas; 2007. Informação completa sobre o uso do Misoprostol para interrupção da gravidez ou tratamento do aborto incompleto.
World Health Organization. Safe abortion: technical and policy guidance for health Systems. Geneva: WHO; 2003. Traz normas para assegurar-se de que os abortos que não se podem evitar sejam seguros. SITES RECOMENDADOS RHL: The WHO Reproductive Health Library. Disponível em: http://apps.who.int/rhl/access/en/index.html. Site com revisões sistemáticas sobre o tema.